Skip to Contents

Hanmi's New Story

Soaring Towards a
Shared Future,
Unveiling
a New Chapter of Hanmi

main3 main3

Innovation

Korea's leading R&D-centric healthcare company.
We create never-before-seen innovation through bold challenges.

main2 main2

Respect, Trust, Integrity

We lead the global healthcare industry
through Respect, Trust, and Integrity.

The Hanmi Way

No path started as a path.
We seek a better future for humanity on it.

View More

Focus on Making
Innovative Medicines

Hanmi Pharmaceutical is leading innovation in the
pharmaceutical industry with a sustainable R&D
infrastructure covering various therapeutic areas.

Obesity/Metabolism

Developing best-in-class drugs for obesity,
non-alcoholic steatohepatitis,
and more with multiple mechanisms of action

View More

ESG Report

Hanmi ESG is Everyday-life Innovation

View More

Your dream is our future.
Hanmi awaits you.

Join Us
Meet Us for 10 presentations at
2024 American Association for Cancer Research (AACR) Annual meeting.

Meet Us for 10 presentations at 2024 American Association for Cancer Research (AACR) Annual meeting.

Unleashing the power of p53 mRNA therapeutics to suppress proliferation of p53 mutant tumors
Abstract Number
LB048
Session
Late-Breaking Research: Experimental and Molecular Therapeutics 1 (Poster), Apr 7 at 1:30 PM ~ 5:00 PM ET, Section 53
Presenter
Yong Ho Heo, Ph.D. /
Hanmi Pharmaceutical

yhheo79@hanmi.co.kr

HM16390, a novel long-acting IL-2 analog with fine-tuned binding affinities to IL-2 receptor subunits for favorable safety profile, exhibits potent tumor killing effect in the various tumor syngeneic models
Abstract Number
LB118
Session
Late-Breaking Research: Immunology 2 (Poster), Apr 8 at 9:00 AM ~ 12:30 PM ET, Section 52
Presenter
Sol-Bi Shin, Ph.D. /
Hanmi Pharmaceutical

solbi.shin@hanmi.co.kr

The immune-modulation of HM16390, firing up the poor tumor microenvironment to induce a potent anti-tumor efficacy
Abstract Number
LB119
Session
Late-Breaking Research: Immunology 2 (Poster), Apr 8 at 9:00 AM ~ 12:30 PM ET, Section 52
Presenter
Jooyun Byun, Ph.D. /
Hanmi Pharmaceutical

jybyun@hanmi.co.kr

Discovery and characterization of potent and selective HER2 exon20 insertion mutant inhibitors
Abstract Number
1970
Session
Kinase and Phosphatase Inhibitors 2 (Poster), Apr 8 at 9:00 AM ~ 12:30 PM ET, Section 25
Presenter
Ho Yeon Nam, Ph.D /
Hanmi Pharmaceutical

hoyeon.nam@hanmi.co.kr

Synthetic lethal strategy of an EZH1/2 dual inhibitor, HM97662, for the treatment of ARID1A-mutated solid cancers
Abstract Number
3240
Session
Epigenetic Targets (Poster), Apr 8 at 1:30 PM ~ 5:00 PM ET, Section 24
Presenter
Gunwoo Lee / Hanmi Pharmaceutical

gunwoo.lee@hanmi.co.kr

A novel and potent IRE1α RNase inhibitor, HM100168 as a promising therapeutic strategy in solid cancers
Abstract Number
3335
Session
Novel Antitumor Agents 3 (Poster), Apr 8 at 1:30 PM ~ 5:00 PM ET, Section 28
Presenter
Jisook Kim, Ph.D. /
Hanmi Pharmaceutical

sook80@hanmi.co.kr

Synergistic effects of EZH1/2 dual inhibition and cisplatin on lung cancer cell lines with loss of SMARCA4 and SMARCA2
Abstract Number
4589
Session
HDAC and Methyltransferase Inhibitors (Poster), Apr 9 at 9:00 AM ~ 12:30 PM ET, Section 24
Presenter
Jeongjae Lee, Ph.D. / Seoul National University Cancer Research Institute

lee_jx2@naver.com

Author
Bhumsuk Keam M.D., Ph.D. / Seoul National University Hospital

bhumsuk@snu.ac.kr

BH3120, PD-L1 X 4-1BB bispecific antibody, plus PD-1 antagonist results in synergistic antitumor efficacy with excellent safety profile
Abstract Number
5300
Session
Immune Modulation Employing Agonist or Co-Stimulatory Approaches (Poster), Apr 9 at 1:30 PM ~ 5:00 PM ET, Section 3
Presenter
Jun Wang MS / Beijing Hanmi Pharmaceutical

wangjun7@bjhanmi.com.cn

Unraveling therapeutic potentials of mRNA-based cancer vaccine concurrently targeting heterogeneous KRAS mutant cancer
Abstract Number
LB352
Session
Late-Breaking Research: Immunology 3 (Poster), Apr 9 at 1:30 PM ~ 5:00 PM ET, Section 53
Presenter
Chang Gyu Lim /
Hanmi Pharmaceutical

changgyu.lim@hanmi.co.kr

Potential activity of TEAD inhibitor in Hippo-altered cancer including NF2 mutant solid cancer and TAZ-CAMTA1 fusion-driven epithelioid hemangioendothelioma (EHE)
Abstract Number
7280
Session
YAP/TAZ/TEAD Modulators (Poster), Apr 10 at 9:00 AM ~ 12:30 PM ET, Section 28
Presenter
Young Gil Ahn, Ph.D. /
Hanmi Pharmaceutical

ygahn@hanmi.co.kr